Filing Flows › Caris Life Sciences (CAI) › Q3 2026
Caris Life Sciences (CAI) Q3 2026 earnings results (third quarter 2026)
10-Q filed Nov 4, 2026
Caris Life Sciences (CAI) reported revenue of $275M for the third quarter 2026 (Q3 2026), +27% from a year earlier and +4% from the quarter before. Operating margin was 7.0%, net earnings $15.2M (5.5% of revenue).
Caris Life Sciences, Q3 2026: revenue $275M (+27% year over year), operating margin 7.0%, net earnings $15.2M, operating cash flow −$22.2M. The chart follows the revenue to costs, profit and cash.
| Q3 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $275M | +4% | +27% |
| Operating profit | $19.3M | -28% | -41% |
| Net earnings | $15.2M | — | -37% |
| Operating cash flow | −$22.2M | -178% | -136% |
What changed
Revenue was $275.4M in Q3 2026, up 27% year over year and up 4% from the previous quarter. Molecular Profiling Services was the largest line at 95% of revenue. Molecular Profiling Services added $55.1M year over year (up 27%), 94% of the total change.
Operating profit was $19.3M, a 7.0% margin (down 8.0 points year over year). Operating profit fell $13.3M even though revenue rose $58.5M versus Q3 2025, so costs grew faster than sales. Total costs grew 39% against revenue growth of 27%. The fastest-growing cost line was Research & development (+56%). Net earnings were $15.2M, down 37% year over year. The effective tax rate was 9.6%.
Operating cash flow was −$22.2M. Non-cash charges added back $6.6M of depreciation and amortization and $18.5M of share-based compensation. Working capital and other items used $62.6M. Capital expenditures of $17.5M exceeded it, leaving free cash flow of −$39.7M.
Questions
What was Caris Life Sciences' revenue in the third quarter 2026?
Caris Life Sciences (CAI) reported revenue of $275M for the third quarter 2026 (Q3 2026), +27% from a year earlier and +4% from the quarter before.
Was Caris Life Sciences profitable in the third quarter 2026?
Operating profit was $19.3M (7.0% of revenue) and net earnings $15.2M.